TY - JOUR
T1 - Sesquiterpene lactone Bigelovin induces apoptosis of colon cancer cells through inducing IKK-β degradation and suppressing nuclear factor kappa B activation
AU - Feng, Yuan
AU - Xia, Jun
AU - Xu, Xin
AU - Zhao, Tong
AU - Tan, Zhengzhi
AU - Wang, Qun
AU - Wang, Jun
AU - Meng, Jia
AU - Sanderson, Christopher
AU - Lu, Zhiliang
AU - Yang, Yili
N1 - Funding Information:
The authors thank Prof. Weidong Zhang from the Navy Medical University (Shanghai, China) for kindly providing sesquiterpene lactone compounds to us. This work was supported by National Natural Science Foundation of China (81973358), Natural Science Foundation of Jiangsu Province (BK20171231), CAMS Initiative for Innovative Medicine (CAMS-I2M, 2016-I2M-1-005), Jiangsu Provincial Science and Technology Department (BM2016006) and Suzhou Municipal Science and Technology Bureau (SZS201716) and XJTLU PGRS/ FOS-16-06.
Publisher Copyright:
© 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Bigelovin, a sesquiterpene lactone extracted from plant Inula helianthus aquatica, exhibited multiple interesting biological activities, including anti-inflammation, antiangiogenesis and cytotoxic action against cancer cells. In the present study, we found that Bigelovin reduced the viability of human colon cancer cells and induced their apoptosis in a time- and dose-dependent manner, with an IC50-5 μM. RNAseq and luciferase reporter analyses revealed that the nuclear factor kappa B (NF-κB) signaling was one of the most significantly inhibited pathways after Bigelovin treatment. Further systemic examination showed that exposure to Bigelovin resulted in ubiquitination and degradation of inhibitor of kappa-B kinase-beta (IKK-β) and decrease of IκB-α and p65 phosphorylation, which led to the downregulation of NF-κB-regulated genes expression. Moreover, enforced expression of exogenous IKK-β attenuated Bigelovin-induced NF-κB suppression and cell viability reduction. These results indicated that Bigelovin exerts a cytotoxic action against colon cancer cells through the induction of IKK-β degradation and consequently the inhibition of NF-κB signaling. Given the abnormal activation of NF-κB signaling in colorectal cancer (CRC) cells and the critical role of chronic inflammation in CRC development, it is conceivable that at least some colorectal cancer cells are addictive to NF-κB activation and targeting the pathway is an effective anti-CRC strategy.
AB - Bigelovin, a sesquiterpene lactone extracted from plant Inula helianthus aquatica, exhibited multiple interesting biological activities, including anti-inflammation, antiangiogenesis and cytotoxic action against cancer cells. In the present study, we found that Bigelovin reduced the viability of human colon cancer cells and induced their apoptosis in a time- and dose-dependent manner, with an IC50-5 μM. RNAseq and luciferase reporter analyses revealed that the nuclear factor kappa B (NF-κB) signaling was one of the most significantly inhibited pathways after Bigelovin treatment. Further systemic examination showed that exposure to Bigelovin resulted in ubiquitination and degradation of inhibitor of kappa-B kinase-beta (IKK-β) and decrease of IκB-α and p65 phosphorylation, which led to the downregulation of NF-κB-regulated genes expression. Moreover, enforced expression of exogenous IKK-β attenuated Bigelovin-induced NF-κB suppression and cell viability reduction. These results indicated that Bigelovin exerts a cytotoxic action against colon cancer cells through the induction of IKK-β degradation and consequently the inhibition of NF-κB signaling. Given the abnormal activation of NF-κB signaling in colorectal cancer (CRC) cells and the critical role of chronic inflammation in CRC development, it is conceivable that at least some colorectal cancer cells are addictive to NF-κB activation and targeting the pathway is an effective anti-CRC strategy.
KW - Apoptosis
KW - Bigelovin
KW - Colorectal cancer
KW - Ikk-β
KW - Nuclear factor kappa b signaling
UR - http://www.scopus.com/inward/record.url?scp=85106192818&partnerID=8YFLogxK
U2 - 10.1097/CAD.0000000000001073
DO - 10.1097/CAD.0000000000001073
M3 - Article
C2 - 33929997
AN - SCOPUS:85106192818
SN - 0959-4973
VL - 32
SP - 664
EP - 673
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 6
ER -